In vitro study | In vitro, CDZ173 inhibits a wide range of immune cell functions such as B cells, T cells, neutrophils, monocytes, basophils, plasmacytoid dendritic cells, and mast cells. At the highest concentrations tested, CDZ173 had no activity against CYP subtypes (3A3, 2D9, 2D6, 2C9), Ion Channel pools (including hREG), protease pools. In a pool of 50 safety-related targets (GPCRs, ion channels, and transporters),CDZ173 had detectable activity only for hPDE4D and 5HT2B, the IC50 values were 4.7 μm and 7.7 μm, respectively. |
In vivo study | CDZ173 inhibited B cell activation in rats and monkeys in a concentration-dependent and time-dependent manner. After prophylactic or therapeutic administration, CDZ173 effectively inhibits antigen-specific antibody production and reduces disease symptoms in a rat collagen-induced arthritis model. CDZ173 can be rapidly absorbed in various species, and quickly reaches Tmax after oral administration, while the clearance rate in rats and monkeys is moderately low, clearance in dogs is very low-so the amount of exposure in the blood is high. CDZ173 binds very high (>99%) to plasma proteins in dogs, while the distribution of compounds is confined to prevention (Vss = 0.3 L/kg). |